Key Studies Influencing My Practice Following EACS 2021

October 27-30, 2021; London, United Kingdom
Read expert faculty members’ summaries of key studies from EACS 2021, including results from studies on BIC/FTC/TAF in a test-and-treat model; islatravir and doravirine in treatment naïve patients; DTG/3TC in patients with an M184V mutation; long-acting CAB + RPV by BMI category, patient satisfaction, and outcomes after discontinuation; lenacapavir in heavily treatment experienced patients; and COVID-19 vaccine effectiveness and the impact of the pandemic on virologic suppression in PWH.
Tristan J. Barber, MA, MD, FRCP
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Jürgen K. Rockstroh, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 697 KB
Released: November 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

This downloadable patient education PDF reviews information on weight gain for people living with HIV initiating antiretroviral therapy

Michelle S. Cespedes, MD, MS Released: April 26, 2022

CCO presenta a la Dra. Leticia M. Pérez Saleme explicando los factores principales a tomar en cuenta cuando se toman decisiones basadas en evidencia para optimizar el TAR en pacientes con supresión virológica en México

Leticia M. Pérez Saleme, MD Released: February 17, 2022

Slides from Dr Jason Schafer and Clinical Care Options (CCO): Antiretroviral stewardship can address key considerations for ART in the inpatient setting.

person default Jason Schafer, PharmD, MPH Released: February 14, 2022

Dr Jason Schafer and Clinical Care Options (CCO): Antiretroviral stewardship can address key considerations for ART in the inpatient setting.

person default Jason Schafer, PharmD, MPH Released: February 7, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings